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Purpose of review — A wide range of dietary carbohydrates, including prebiotic food ingredients, fermentable
fibers, and milk oligosaccharides, are able to produce significant changes in the intestinal microbiota. These shifts
in the microbial community are often characterized by increased levels of bifidobacteria and lactobacilli. More recent studies have revealed that species of Faecalibacterium, Akkermansia, and other less well studied members
may also be enriched. We review the implications of these recent studies on future design of prebiotics and synbiotics to promote gastrointestinal health.
Recent findings — Investigations assessing the clinical outcomes associated with dietary modification of the gut
microbiota have shown systemic as well as specific health benefits. Both prebiotic oligosaccharides comprised of
a linear arrangement of simple sugars, as well as fiber-rich foods containing complex carbohydrates, have been
used in these trials. However, individual variability and nonresponding study participants can make the outcome
of dietary interventions less predictable. In contrast, synergistic synbiotics containing prebiotics that specifically
stimulate a cognate probiotic provide additional options for personalized gut therapies.
Summary — This review describes recent research on how prebiotics and fermentable fibers can influence the
gut microbiota and result in improvements to human health.
Keywords: fiber, gut microbiota, oligosaccharides, prebiotics, probiotics, synbiotics

Introduction

(GIT) [4]. In the past two decades, appreciable experimental and clinical evidence has emerged suggesting that
prebiotics may promote gastroenterological homeostasis and/or redress specific disease states associated with
microbial imbalance (i.e., dysbiosis) [5*].
Like prebiotics, probiotics have also long been used as
therapeutic agents for improving gastrointestinal health.
However, most probiotic microorganisms are allochthonous to the intestinal environment and are generally unable to colonize or persist in the GIT [6,7]. Prebiotics have
a decided advantage by enriching for organisms already
present in the gut ecosystem (so-called autochthonous
members). Fermentation of prebiotic carbohydrates yields
butyrate and other short chain fatty acids, as well as other
end products that lower the local pH, stimulate mucin

Despite the considerable research attention recently
devoted to diet and microbiota, the notion that dietary
components can influence gastrointestinal microbiota
composition and enhance host health is not new. Indeed,
this very hypothesis was envisioned more than a century
ago, long before any specific foods or food constituents
had been identified and before techniques for assessing
microbiota complexity could be appreciated [1,2]. One of
the first specific dietary components to be recognized for
its unique impact on the gut microbiota was breast milk
[3]. Eventually, the prebiotic concept was introduced to
describe those food ingredients or constituents that enrich for beneficial organisms in the gastrointestinal tract
110
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Table 1. Simple and complex prebiotics

Key Points

Simple

Complex

● The human gut microbiota is profoundly influenced by
prebiotic food ingredients as well as fermentable fibers and oligosaccharides found in human milk.
● Shifts in the gut microbiota are associated with positive
systemic as well as specific health outcomes although
clinical data are equivocal, in part because some individuals do not respond to prebiotic treatments.
● Dietary strategies based on mixtures of prebiotic fibers
or rationally designed synbiotic approaches may be
more effective at modulating the gut microbiota.

Inulin

Pectins

Galactooligosaccharide

Resistant starch

production by colonocytes, and induce production of immunomodulatory cytokines [8]. Thus, prebiotics not only
cause shifts in the microbiota by supporting growth of
particular GIT members but also serve as substrates for
production of biologically active metabolites.
Prebiotics now provide food formulators, as well as clinicians, with rather simple diet-based opportunities to influence the composition of the gut microbiota and improve intestinal health. In this review, we describe current
strategies for how prebiotic approaches can be used to
achieve these goals. Specifically, we address the prebiotic
activity of fiber-rich foods, why some individuals respond
to prebiotics and others do not, and the advantages of
rational or synergistic synbiotics for inducing beneficial
shifts in the gastrointestinal microbiota.
Prebiotics in 2016: Emerging Concepts
Despite the substantial industrial and clinical interest
in prebiotics, the commercial market has been dominated
by only a handful of prebiotics, mainly inulin, fructooligosaccharides, and galactooligosaccharides (GOS) [9,10].
Several isomaltooligosaccharides products are also commercially available [11]. In the United States, European
Union, and Pacific Rim, these prebiotics are added as functional ingredients in a wide variety of processed foods
and beverages. Infant formula products, in particular, are
often supplemented with GOS or fructooligosaccharides
because of their ability to mimic a bifidogenic response
similar to that which occurs with human milk oligosaccharides in breast-fed infants [12,13].
Also documented to have prebiotic activity are resistant starches, starches that are resistant or slowly resistant to digestion and reach the colon intact. Depending
on the type of resistant starches, studies have shown they
enhance growth of bifidobacteria, as well as Eubacterium

Fructooligosaccharide

Isomaltooligosaccharide

Mannan oligosaccharide

Human milk oligosaccharide
Arabinoxylan

Adapted from [22].

rectale, Ruminococcus bromii, and lactobacilli [5*,14–17].
Some of these changes in the microbiota are correlated
with glycemic improvements [18] and high butyrate production [19]. The latter could be favorable for the prevention of colon cancer and inflammation [20,21]. In general,
these commercial prebiotics consist of mostly linear oligosaccharides or polysaccharides that contain only one
or two monomeric sugars (Table 1) [22].
There is also considerable evidence showing that several dietary fibers have prebiotic activity [23*]. In contrast
to the rather simple, linear composition of commercial
prebiotics, the carbohydrates in plants as well as those
present in human milk (Table 1) are diverse and structurally complex, with many containing functional groups
[13,24*,25]. In the gut, they require participation of a
more extensive and diverse array of hydrolytic enzymes
to degrade these molecules into fermentable substrates
[24*,26**]. Accordingly, there may be different host-dependent responses, as the specific form or type of dietary
fiber consumed by an individual may differentially affect
the response of the microbiota [26**,27].
Prebiotic fibers are often natural constituents of a variety of foods, especially whole grains, fruits, root and other
vegetables, and legumes. Although some foods contain
appreciable concentrations of these prebiotics [28], in
most western diets, consumption of these fiber-rich foods
is probably too low to contribute much fermentable fiber to the colon. However, for individuals who consume
whole grain products and fiber-rich diets, significant effects on the microbiota have been observed, with shifts
in the abundance of specific taxa and increased microbial diversity [18,23*,29]. In contrast, other studies have
shown that whole grain consumption does not always induce changes in gut microbiota [30] or consistently affect
clinical end points [31].
Based on these observations, several researchers have
suggested that prebiotics are best defined based on their
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physiological effects or functional capacities rather than
the specific microbial targets affected [32*,33]. So-called
second generation prebiotics were envisioned as providing specific functional benefits. According to this argument, dietary fibers may have prebiotic activity by causing broad changes in community structure, but without
necessarily influencing abundances of bifidobacteria or
lactobacilli [34].
It is worth noting that the convergence of “prebiotics”
and “fiber” has led to the development of a new lexicon
in the prebiotic community [35]. Indeed, “low-digestible”
[36] and “nondigestible carbohydrates” [37], “prebiotic fiber” [34], “functional fiber”, and “fermentable fiber” [38]
are among the terms used to describe the food carbohydrates that have microbiome-influencing properties. Neither is there consensus on definitions of prebiotics nor the
specific types of fiber [38,39]. Recently, Sonnenburg and
Sonnenburg [40**] introduced the term “microbiota- accessible carbohydrate” (MAC) to describe fibers, as well as
host-secreted mucin and microbial-produced saccharides,
that are available as substrates for the gut community. The
absence of these fibers in the colon (as a result of low-fiber diets) may result in gut microbes looking elsewhere
for sugars, namely, the mucin layer that protects the host.
Prebiotics, the Healthy Gut Microbiota, and the
Challenge of Individual Variation
Although several microbial taxa or genera have been
suggested as being beneficial to the host (i.e., Bifidobacterium and Lactobacillus spp. [41,42]), there is still no actual definition of what constitutes a healthy gut microbiota [32*,43]. One recent study showed that gut microbiota
from healthy human hunter gatherers was significantly different from a healthy western cohort, suggesting that the
ideal or optimal composition of an individual’s gut microbiota depends on the lifestyle of the individual [44]. Although enrichment of specific taxa by diet is possible, the
clinical significance of these changes may not be readily
apparent. Indeed, organisms not previously recognized
as contributing to host heath, including Eubacteria, Faecalibacter, Akkermansia, Ruminococcus, and Roseburia, are
known to respond to prebiotics [5*,16,45,46*]. Finally, several microorganisms categorized previously as detrimental are now recognized as part of the gut “normobiosis”
and may even be beneficial. For example, Clostridia spp.
have recently been shown to be beneficial in the attenuation of diseases in models of colitis and allergic diarrhea [42,47,48].
Significant interindividual variability [49] can also make
the outcome of dietary interventions less predictable.

Indeed, multiple studies have reported the occurrence of
study participants who respond to prebiotics and other dietary treatments (responders), whereas in similar studies,
study participants fail to respond (nonresponders) to the
same treatments [14,43,50,51]. Responses to dietary interventions likely depend on the taxonomic and functional
composition of the gut microbiota. Thus, when a given
compound is selectively fermented by a limited number of
bacteria (fulfilling the actual definition of prebiotic) the response will depend on the gene content and functionality
of the target bacteria before supplementation. The presence of species known to metabolize certain compounds,
however, is not a guarantee of a positive response to prebiotic supplementation. For instance, dietary interventions
in obese study participants resulted in decreased cholesterol concentrations, but only in individuals with high initial levels of Clostridium sphenoides [43]. Furthermore, Davis et al. [52] showed that a fraction of study participants
who had consumed as much as 10 g GOS/day for 3 weeks
did not respond to the treatment, even though they harbored bifidobacteria at similar levels as that of responders. The authors suggested that nonresponders may lack
specific strains capable of metabolizing GOS [52].
The ability of a particular species to ferment certain
prebiotics is strain specific [53–55]. Thus, GIT environments having a similar taxonomic assembly might differ
in functional capabilities and therefore result in different
responses to prebiotics interventions. Moreover, although
a given strain may have the biochemical and physiological means to transport and metabolize a prebiotic, it must
also outcompete other autochthonous members of the
microbiota to actually utilize the prebiotic compounds
and potentially expand its population [52]. Ultimately, the
complexity and individuality of the gut microbiota and the
structural complexity of dietary fibers likely contribute to
the phenomenon of responders and nonresponders.
As a practical strategy, consumption of fermentable fiber or combinations of prebiotics may enrich for a larger
and more diverse population of gut microbes. This strategy could potentially reduce the occurrence of nonresponders. In addition, stimulating a broader spectrum
of microorganisms, either directly or via cross-feeding,
could also promote greater diversity within the gut ecosystem. High levels of diversity are generally considered
important for a functional gut ecosystem [56]. Several
human gastrointestinal diseases are associated with reduced microbial diversity and gene richness [5*]. In particular, reductions in Firmicutes are frequently described
[57]. Reduced diversity has also been reported to have
an impact on the production of beneficial metabolites by
gut microbes. For example, antibiotic treatments and diarrheal disease are characterized by reduced or altered
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production of short chain fatty acids [58,59]. In contrast,
increased diversity has been associated with an improvement in insulin sensitivity [60]. Furthermore, and perhaps
most importantly, the restoration of a diverse gut microbiota is associated with successful treatments for C. difficile infections [61*].
Ultimately, the success of a prebiotic treatment depends on its ability to enhance health or reduce a disease
phenotype. Several meta-analyses and systematic reviews
of human trials with various prebiotics have been conducted with various end points assessed (Table 2) [62–71].
In general, these analyses have shown that commercial
prebiotics were effective for some conditions (i.e., constipation and diarrhea), but not others (i.e., cholesterol reduction and eczema).
Synbiotics to the Rescue
Although some attempts to predict responses to dietary interventions based on the microbial composition of
the gut prior to prebiotic consumption [43] have proven
successful, it remains a challenge for practitioners and dietitians to recommend specific prebiotics to patients because of highly individualized responses. Accordingly,
when rationally formulated, synbiotics may provide an
effective strategy to enhance persistence and metabolic
activity of specific beneficial probiotic strains. The most
commonly used synbiotic combinations contain lactobacilli and bifidobacteria, as the probiotic component, and
oligosaccharides, inulin, or fibers as the prebiotic component [72]. Despite the potential advantages of these
products, however, how these synbiotics are specifically
formulated can have considerable influence on their potential effectiveness.
When the synbiotic concept was first introduced [4],
two configurations were proposed. Either the prebiotic
and probiotic components are chosen independently of
one another, with each responsible for a particular effect
or health benefit (complementary synbiotics); or the synbiotic combination is specifically designed with a prebiotic substrate synergistically supporting the competitiveness, survival, or metabolic activity of a cognate probiotic
strain in the gastrointestinal ecosystem (synergistic synbiotics) [73]. These synergistic synbiotics have the potential
advantage of functioning even in prebiotic nonresponders,
since they would not require the presence of responder
strains. Furthermore, the incorporation of a selective fermentable substrate represents a resource opportunity that
increases the competitive fitness of the partner organism
and could enhance its persistence [74].
Although several meta-analyses of synbiotic trials
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suggest clinical benefits (Table 3) [62,71,75–77], most trials have lacked experimental power or were designed such
that the treatment effects could not be determined, that
is, the treatment effects of the pro and prebiotic were not
determined independently. Additionally, microbial analyses either were absent in several studies or the analytical methods were conducted at higher taxonomical levels
and were not strain specific. Thus, only very few studies
showed that the synbiotic had functioned synergistically in
vivo [78,79,80*,81,82]; only one of these studies was conducted in humans [82].
As noted above, for most synbiotic products, selection of pro and prebiotic pairs has been based on arbitrary considerations [80*] rather than on rational selection
of synbiotic constituents. Although in-vitro screenings of
potential synbiotic combinations are routinely used, such
approaches do not account for ecological efficacy or effectiveness [83–88]. Moreover, in-situ predictions for how
an individual will respond to prebiotics based on genome
content may also be limited, in part, because they do not
account for competitiveness and other interactions with
autochthonous members of the gut microbiota (i.e., crossfeeding and predation) [52,89,90]. Nonetheless, such analyses can be a valuable first step toward designing synergistic synbiotics.
Recently, two novel approaches, both based on ecological performance or fitness, have been proposed for
developing synergistic synbiotics. The in-vivo selection
method relies on the selection and isolation of strains
whose abundance is significantly enriched in study participants who had consumed a given prebiotic [80*]. When
recombined as a synbiotic and introduced into a new host,
these strains would be expected to colonize at greater
levels than in the absence of the prebiotic. This approach
was recently tested in an animal model. The synbiotic consisted of a strain of B. adolescentis (IVS-1) that had been
enriched by GOS in a single human study participants [52].
When combined with GOS and fed to rats, the abundance
of B. adolescentis increased to about 30% of the total population [80*].
The other approach, called multitaxon INsertion Sequencing, uses libraries of transposon mutants of bacterial
strains with probiotic interest to identify genes that determine the fitness of that bacteria in response to a prebiotic treatment [91*]. Not only are bacteria that are specifically responsive to the treatment recognized in vivo
but also the genes that drive the response are identified.
As the authors state, however, this promising technique
currently cannot distinguish between primary effects induced by the diet and secondary community driven, ecological effects.

Outcome

Kellow et al.
Metabolic health
5 trials (n=52)
<0.05
Oligofructose, chicory(2014) [65]				
derived fructan
		
5 trials (n=208)
0.16
Oligofructose, inulin,
				
ALA, FOS
		
4 trials (n=131)
<0.05
Oligofructose, chicory				
derived fructan, FOS,
				
inulin
		
3 trials (n=121)
<0.05
Oligofructose, inulin,
				
FOS
					

Zaman et al.
Diarrhea in patients
6 trials (n=354)
0.77 		
(2015) [64]
receiving EN
		
8 trials (n=568)
<0.00001 Fiber
					
		
3 trials (n=157)
0.81
Prebiotics

Normal-weight,
overweight and
obese patients

Satiety is not promoted

Overweight patients
or type II diabetes
Normal-weight and
obese patients

Reduced postprandial insulin
concentrations

Reduced postprandial glucose
concentrations

Satiety is promoted

Reduced diarrhea in not critically ill
patients
Effect is inconclusive

Healthy adults

EN patients, not
critically ill
EN patients

Reduced diarrhea in critically ill patients

Reduced diarrheal episodes

Reduced antibiotic treatment

EN patients, critically ill 		

Oligofructose,
Infants and children
GOS/FOS
(sc)GOS, (lc)FOS,		
oligofructose
Oligofructose, GOS/FOS 		

Reduced febrile episodes

Study participants

Lohner et al.
Acute infectious
2 trials (n=715)
0.34
(2014) [63]
diseases			
		
3 trials (n=671)
<0.00001
				
		
3 trials (n=747)
0.34

Type of prebiotic
No significant reduction in total
cholesterol
No significant reduction in LDL-c levels.
No significant reduction in fasting
glucose
Significant reduction in fasting insulin
Prebiotic tends to increase HDL-c
No significant reduction in triglyceride
levels

Studies and study
participants included P value

Beserra et al.
Total cholesterol
9 trials (n=313)
0.314
FOS, GOS, inulin, or
Overweight or obese
(2015) [62]				
oligofructose
adults
		
9 trials (n=278)
0.496 			
		
9 trials (n=278)
0.621 			
						
		
8 trials (n=219)
0.081 			
		
10 trials (n=313)
0.438 			
		
10 trials (n=313)
0.156 			
						

		
Author/year
Disease phenotype

Table 2. Overview of meta-analyses on prebiotics
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Studies and study
participants included P value
Type of prebiotic

Study participants

Fiber has a significant benefit for
treating IBS
Bran has no benefit in IBS treatment
Supplementation was safe, no decreased
incidence of NEC or late onset sepsis

No significant effects of prebiotic
consumption on development of
eczema in infants. No consistent
changes for sensitization

Significant reduction of risk of no
improvement of MHE with no intertrial
heterogeneity

Moayyedi et al.
IBS
15 trials (n=590)
0.0005
Bran, ispaghula, linseeds,
Patients with IBS
(2014) [68]				
fiber (unspecified)		
		
6 trials (n=441)
0.14 			

Srinivasjois et al.
NEC
5 trials (n=345)
NG
scGOS+lcFOS; lactulose 		
(2013) [69]						
Late onset sepsis
3 trials (n=295)
0.23
scGOS+lcFOS; lactulose

Dang et al. (2013) Development of
3 trials (n=510)
>0.05
scGOS+lcFOS+pAOS;
Infants (1–2 years;
[70]
eczema			
scGOS+lcFOS;
4 months)
				
PDX+GOS+LOS		
						

Shukla et al.
MHE
5 trials (n=117)
<0.0001
Lactulose
Adults
(2011) [71]						
						

EN, enteral nutrition; FOS, fructooligosaccharides; GOS, galactooligosaccharides; IBS, irritable bowel syndrome; lc, long chain; MHE, minimal hepatic encephalopathy; NEC, necrotizing enterocolitis;
NG, not given, Sc, short chain.

Improved stool consistency
Improved food transit time
Improved stool hardness
No improvement for pain and bloating

Improved stool frequency

Fiber reduces serum creatinine
Fiber has no effect on serum phosphorus

Fiber reduces serum urea

Outcome

Collado Yurrita
Bowel function
5 trials (n=144)
NG
Inulin
Adults with chronic
et al. (2014) [67]					
constipation
		
2 trials (n=96) 				
		
2 trials (n=80) 				
		
2 trials (n=80) 				
		
2 trials (n=80) 				

Chiavaroli et al.
Chronic kidney
13 trials (n=150)
0.006
Inulin, fermentable fibers,
Patients with chronic
(2014) [66]
disease			
arabinogalactan, gum,
kidney disease or
				
lactulose, high- vs.
on hemodialysis
				
low-fiber foods
		
12 trials (n=117)
0.02 			
		
7 trials (n=72)
0.47
Inulin, fiber, lactulose,		
				
wheat bran, high-fiber
				
foods

		
Author/year
Disease phenotype
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Studies and study
participants
P value

Type of synbiotic

Study participants

Synbiotics failed to improve growth rate
but significantly improved stool
frequency

Reduced plasma triglyceride
concentrations
No significant changes were observed
for total cholesterol, LDL-c, HDL-c
and fasting glucose

Reduced plasma fasting insulin
concentrations

Synbiotics reduced the length of
postoperative antibiotic use
No significant changes were observed
for prevention of pneumonia, wound
infection, urinary tract infection,
mortality, and length of hospital stay

The incidence of postoperative sepsis
was reduced by synbiotic treatment

Beneficial for chronic idiopathic
constipation treatment

No reduced symptoms of IBS

Synbiotic use reduced the risk of no
improvement of minimal hepatic
encephalopathy

Outcome

Prebiotic type: BG, β-glucan; FOS, fructooligosaccharides; GOS, galactooligosaccharides; HE, hepatic encephalopathy; I, inulin; NG, not given; OAF, oat fiber; OF, oligofructose; P, pectin; RS,
resistant starch; Sc, short chain.

Probiotic type: BB, Bifidobacterium breve; BB2, Bifidobacterium bifidum; BL, Bifidobacterium longum; BL2, Bifidobacterium lactis; BM, Bacillus mesentericus; CB, Clostridium butyricum; EF,
Enterococcus faecium; LA, Lactobacillus acidophilus; LB, Lactobacillus bulgaricus; LC, Lactobacillus casei; LL, Lactococcus lactis; LM, Leuconostoc mesenteroides; LP, Pediococcus pentoseceus; LP2,
Lactobacillus plantarum; LP3, Lactobacillus paracasei; LPSP, Lactobacillus paracasei subsp. paracasei; LR, Lactobacillus rhamnosus; LS, Lactobacillus salivarius; LS2, Lactobacillus sporogenes; PP,
Pediococcus pentosaceus; ST, Streptococcus thermophiles.

Mugambi et al.
Growth and stool
2 trials (n=227)
0.29
Probiotic: BL, LR, LP3;
Infants
(2012) [77]
frequency			
prebiotic: GOS, ScFOS		
						
		
2 trials (n=122)
0.006
Probiotic: BL; prebiotic: GOS,
				
FOS

Glycemia, insulin
2 trials (n=364)
0.04
Probiotic: BL, LC, LR, ST, BB,
Adult patients with
concentrations and 			
LA, LB; prebiotic: FOS
overweight or
lipid parameters 				
obesity
		
3 trials (n=260)
<0.05
Probiotic: LS2, BL, LA, BB;		
				
prebiotic: I, FOS		
		
2, 3 or 4 trials each
NG
Probiotics: LC, LR, ST, BB, LA,		
		
(n varying between		
BL, LB, LS2; prebiotic: I, FOS		
		
49 and 104)				

Probiotic: LC, LP2, LP3, LM,
Patients undergoing
LA, LB, BL2, ST, PP, BB, EF,
elective surgery
CB, BM, LS, BB2, LL; prebiotic:
OAF, OF, BG, I, P, RS, GOS
Probiotic: PP, LM, LP2; 		
prebiotic: BG, I, P, RS		
Probiotic: LC, LP2, LP3, LM, LA,		
LB, BL2, ST, PP, BB, EF, CB,		
BM, LS, BB2, LL; prebiotic:		
OAF, OF, BG, I, P, RS, GOS		

Kinross et al.
Clinical outcome
8 trials (n=361)
0.002
(2013) [76]
after elective surgery			
				
				
		
4 trials (n=135)
0.03
				
		
2 or 3 trials each
>0.05
		
(n varying between		
		
198 and 260)		
				

Bessera et al.
(2015) [62]

Probiotic: BL2, LP3, LR, LA;		
prebiotic: FOS		

		
2 trials (n=160)
0.003
				

Shukla et al.
HE
1 trial (n=55)
0.004
Probiotic: PP, LM, LPSP, LP2;
HE patients
(2011) [71]				
prebiotic: BG, I, P, RS		
						
		
1 trial (n=60) 		
Probiotic: BL; prebiotic: FOS,
				
vitamins B1, B2, B6, B12
Ford et al.
IBS and chroic
2 trials (n=198)
0.09
Probiotic: BL, BB, LR, LA, LB,
IBS patients
(2014) [75]
idiopathic constipation		
ST,LC; prebiotic: FOS

		
Author/year
Disease phenotype

Table 3. Overview of meta-analyses on synbiotics
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Conclusion
More than a century ago, Nobel laureate, Ilya Metchnikoff wrote “The dependence of the intestinal microbes
on the food makes it possible to adopt measures to modify the flora in our bodies and to replace the harmful microbes by useful microbes” [92]. Noting the experimental
challenges implied by this goal, Metchnikoff added that
“Notwithstanding this difficulty, however, a rational solution of the problem must be sought.” These experimental difficulties no longer exist, and the ability to modulate
the gastrointestinal microbiota by prebiotic fibers and rational synbiotics is now possible. Current efforts to relate
shifts in the microbiota, and specific taxa, in particular, to
health and disease or to affect a clinically proven health
benefit, may well lead to well tolerated and effective therapies for improving human health. In particular, formulation of synergistic synbiotics containing strains having established health benefits may provide opportunities for
personalized treatments.
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Company, and Bio- Gaia. He also serves on the Board of Directors of the International Scientific Association for Probiotics
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